dc.contributor.author | Penault-Llorca, F | |
dc.contributor.author | Dalenc, F | |
dc.contributor.author | Chabaud, S | |
dc.contributor.author | Cottu, P | |
dc.contributor.author | Allouache, D | |
dc.contributor.author | Cameron, D | |
dc.contributor.author | Grenier, J | |
dc.contributor.author | Venat Bouvet, L | |
dc.contributor.author | Jegannathen, A | |
dc.contributor.author | Campone, M | |
dc.contributor.author | Debled, M | |
dc.contributor.author | Hardy-Bessard, A-C | |
dc.contributor.author | Giacchetti, S | |
dc.contributor.author | Barthelemy, P | |
dc.contributor.author | Kaluzinski, L | |
dc.contributor.author | Mailliez, A | |
dc.contributor.author | Mouret-Reynier, M-A | |
dc.contributor.author | Legouffe, E | |
dc.contributor.author | Cayre, A | |
dc.contributor.author | Martinez, M | |
dc.contributor.author | Delbaldo, C | |
dc.contributor.author | Mollon-Grange, D | |
dc.contributor.author | Macaskill, EJ | |
dc.contributor.author | Sephton, M | |
dc.contributor.author | Stefani, L | |
dc.contributor.author | Belgadi, B | |
dc.contributor.author | Winter, M | |
dc.contributor.author | Orfeuvre, H | |
dc.contributor.author | Lacroix-Triki, M | |
dc.contributor.author | Bonnefoi, H | |
dc.contributor.author | Bliss, J | |
dc.contributor.author | Canon, J-L | |
dc.contributor.author | Lemonnier, J | |
dc.contributor.author | Andre, F | |
dc.contributor.author | Bachelot, T | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2024-08-02T13:50:13Z | |
dc.date.available | 2024-08-02T13:50:13Z | |
dc.date.issued | 2024-05-01 | |
dc.identifier | ARTN 103443 | |
dc.identifier | S2059-7029(24)01211-0 | |
dc.identifier.citation | ESMO Open, 2024, 9 (5), pp. 103443 - | en_US |
dc.identifier.issn | 2059-7029 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6338 | |
dc.identifier.eissn | 2059-7029 | |
dc.identifier.eissn | 2059-7029 | |
dc.identifier.doi | 10.1016/j.esmoop.2024.103443 | |
dc.identifier.doi | 10.1016/j.esmoop.2024.103443 | |
dc.description.abstract | BACKGROUND: The purpose of this study was to evaluate the prognostic value of the multigene EndoPredict test in prospectively collected data of patients screened for the randomized, double-blind, phase III UNIRAD trial, which evaluated the addition of everolimus to adjuvant endocrine therapy in high-risk, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. PATIENTS AND METHODS: Patients were classified into low or high risk according to the EPclin score, consisting of a 12-gene molecular score combined with tumor size and nodal status. Association of the EPclin score with disease-free survival (DFS) and distant metastasis-free survival (DMFS) was evaluated using Kaplan-Meier estimates. The independent prognostic added value of EPclin score was tested in a multivariate Cox model after adjusting on tumor characteristics. RESULTS: EndoPredict test results were available for 768 patients: 663 patients classified as EPclin high risk (EPCH) and 105 patients as EPclin low risk (EPCL). Median follow-up was 70 months (range 1-172 months). For the 429 EPCH randomized patients, there was no significant difference in DFS between treatment arms. The 60-month relapse rate for patients in the EPCL and EPCH groups was 0% and 7%, respectively. Hazard ratio (HR) supposing continuous EPclin score was 1.87 [95% confidence interval (CI) 1.4-2.5, P < 0.0001]. This prognostic effect remained significant when assessed in a Cox model adjusting on tumor size, number of positive nodes and tumor grade (HR 1.52, 95% CI 1.09-2.13, P = 0.0141). The 60-month DMFS for patients in the EPCL and EPCH groups was 100% and 94%, respectively (adjusted HR 8.10, 95% CI 1.1-59.1, P < 0.0001). CONCLUSIONS: The results confirm the value of EPclin score as an independent prognostic parameter in node-positive, hormone receptor-positive, HER2-negative early breast cancer patients receiving standard adjuvant treatment. EPclin score can be used to identify patients at higher risk of recurrence who may warrant additional systemic treatments. | |
dc.format | Print-Electronic | |
dc.format.extent | 103443 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | ELSEVIER | en_US |
dc.relation.ispartof | ESMO Open | |
dc.subject | EndoPredict | |
dc.subject | breast cancer | |
dc.subject | endocrine therapy | |
dc.subject | prognostic biomarker | |
dc.subject | risk stratification | |
dc.subject | Humans | |
dc.subject | Female | |
dc.subject | Breast Neoplasms | |
dc.subject | Middle Aged | |
dc.subject | Prognosis | |
dc.subject | Receptor, ErbB-2 | |
dc.subject | Double-Blind Method | |
dc.subject | Aged | |
dc.subject | Adult | |
dc.subject | Receptors, Estrogen | |
dc.subject | Receptors, Progesterone | |
dc.subject | Everolimus | |
dc.subject | Disease-Free Survival | |
dc.subject | Biomarkers, Tumor | |
dc.title | Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2024-04-04 | |
dc.date.updated | 2024-08-02T13:47:12Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1016/j.esmoop.2024.103443 | en_US |
rioxxterms.licenseref.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
rioxxterms.licenseref.startdate | 2024-05-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/38692082 | |
pubs.issue | 5 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.esmoop.2024.103443 | |
pubs.volume | 9 | |
icr.researchteam | Clin Trials & Stats Unit | en_US |
dc.contributor.icrauthor | Bliss, Judith | |
icr.provenance | Deposited by Mr Arek Surman on 2024-08-02. Deposit type is initial. No. of files: 1. Files: Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-ne.pdf | |